Key result
Current smoking in patients with CKD was associated with a higher risk of vascular events compared to never smokers (RR 1.36; 95% CI 1.19-1.55), but not with kidney disease progression.
Why the study?
Does smoking increase the risk of vascular events, cancer, ESRD, and mortality in patients with chronic kidney disease?
Observational (n=9,270)
Does smoking increase the risk of vascular events, cancer, ESRD, and mortality in patients with chronic kidney disease?
Relative Risk: 1.36 (95% CI 1.19–1.55)
In patients with CKD, smoking significantly increases the risk of vascular events and mortality, but is not associated with kidney disease progression.
May support smoking cessation counseling in CKD to reduce vascular events; leaves open effects on progression.
BACKGROUND: The absolute and relative importance of smoking to vascular and nonvascular outcomes in people with chronic kidney disease (CKD), as well its relevance to kidney disease progression, is uncertain. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 9,270 participants with CKD enrolled in SHARP. PREDICTOR: Baseline smoking status (current, former, and never). OUTCOMES: Vascular events, site-specific cancer, ESRD, rate of change in estimated glomerular filtration rate (eGFR), and cause-specific mortality. RESULTS: At baseline, 1,243 (13%) participants were current smokers (median consumption, 10 cigarettes/day); 3,272 (35%), former smokers; and 4,755 (51%), never smokers. Median follow-up was 4.9 years. Vascular event rates were 36% higher for current than never smokers (2,317 events; relative risk [RR], 1.36; 95% CI, 1.19-1.55), reflecting increases in both atherosclerotic (RR, 1.49; 95% CI, 1.26-1.76) and nonatherosclerotic (RR, 1.25; 95% CI, 1.05-1.50) events. Cancer was 37% higher among current smokers (632 events; RR, 1.37; 95% CI, 1.07-1.76), with the biggest RRs for lung (RR, 9.31; 95% CI, 4.37-19.83) and upper aerodigestive tract (RR, 4.87; 95% CI, 2.10-11.32) cancers. For 6,245 patients not receiving dialysis at baseline, ESRD incidence did not differ significantly between current and never smokers (2,141 events; RR, 1.02; 95% CI, 0.89-1.17), nor did estimated rate of change in eGFR (current smokers, -1.77±0.14 [SE]; never smokers, -1.70±0.07mL/min/1.73m(2) per year). All-cause mortality was 48% higher among current smokers (2,257 events; RR, 1.48; 95% CI, 1.30-1.70), with significant increases in vascular (RR, 1.35; 95% CI, 1.07-1.69) and nonvascular (RR, 1.60; 95% CI, 1.34-1.91) causes of death, especially cancer (RR, 2.32; 95% CI, 1.58-3.40) and respiratory (RR, 2.25; 95% CI, 1.51-3.35) mortality. LIMITATIONS: Smoking status not assessed during follow-up. CONCLUSIONS: In this study of patients with CKD, smoking significantly increased the risks for vascular and nonvascular morbidity and mortality, but was not associated with kidney disease progression. The associations with vascular and neoplastic disease are in keeping with those observed in the general population and are likely modifiable by cessation.
No takes yet. Share an insight, caveat, or question.
Staplin et al. (2016) conducted an observational in Chronic kidney disease (CKD) (n=9,270). Current smoking vs. Never smokers was evaluated on Vascular events (RR 1.36, 95% CI 1.19-1.55). Current smoking in patients with CKD was associated with a higher risk of vascular events compared to never smokers (RR 1.36; 95% CI 1.19-1.55), but not with kidney disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: